ULK1 and osteoporosis: To examine whether ULK1 could serve as a potential therapeutic target for bone loss in osteoporosis, an ovariectomized osteoporosis mouse model was established, and then, ULK1 activator (LYN-1604) or saline (Figure 5(a)) was administered by intraperitoneal injection.